NZ334595A - Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage - Google Patents

Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage

Info

Publication number
NZ334595A
NZ334595A NZ334595A NZ33459597A NZ334595A NZ 334595 A NZ334595 A NZ 334595A NZ 334595 A NZ334595 A NZ 334595A NZ 33459597 A NZ33459597 A NZ 33459597A NZ 334595 A NZ334595 A NZ 334595A
Authority
NZ
New Zealand
Prior art keywords
bond
peptide
alpha
enzymatic cleavage
formula
Prior art date
Application number
NZ334595A
Other languages
English (en)
Inventor
Bjarne Due Larsen
Arne Holm
Original Assignee
Zealand Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharmaceuticals As filed Critical Zealand Pharmaceuticals As
Publication of NZ334595A publication Critical patent/NZ334595A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ334595A 1996-09-09 1997-09-09 Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage NZ334595A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK97296 1996-09-09
PCT/DK1997/000376 WO1998011126A1 (fr) 1996-09-09 1997-09-09 Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide

Publications (1)

Publication Number Publication Date
NZ334595A true NZ334595A (en) 2000-08-25

Family

ID=8099572

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ334595A NZ334595A (en) 1996-09-09 1997-09-09 Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage

Country Status (8)

Country Link
EP (1) EP0932614A1 (fr)
JP (1) JP2001505872A (fr)
KR (1) KR20000036015A (fr)
AU (1) AU724326B2 (fr)
CA (1) CA2265454A1 (fr)
IL (1) IL128828A0 (fr)
NZ (1) NZ334595A (fr)
WO (1) WO1998011126A1 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6278298A (en) * 1997-02-14 1998-09-08 Salk Institute For Biological Studies, The Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (fr) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
US7671029B2 (en) 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
US6908900B2 (en) 2001-01-17 2005-06-21 Zimmer & Associates Ag Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
CA2389233A1 (fr) * 1999-10-29 2001-05-10 Paul K. S. Nam Oligomeres et segments oligomeres d'acides .alpha.-hydroxycarboxyliques et d'acides .alpha.-amines
US6939693B2 (en) 1999-10-29 2005-09-06 Novus International, Inc. Enantioselective oligomerization of α-hydroxy carboxylic acids and α-amino acids
DE10018617A1 (de) * 2000-01-13 2001-10-31 Joerg G Moser Cyclodextrin-Dimere mit Peptid-Spacerstrukturen zur Entgiftung von pharmazeutischen Wirkstoffen hohen Nebenwirkungspotentials
AU2001293995B2 (en) 2000-10-09 2005-10-13 Cytomx Therapeutics, Inc. Therapeutic antibodies
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
AU2005337116A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
JP2009508886A (ja) 2005-09-21 2009-03-05 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ２選択性レセプターアゴニスト
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
EP3492488A1 (fr) 2007-08-22 2019-06-05 The Regents of The University of California Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
WO2009058662A2 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Antagonistes du glucagon
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
KR20110040760A (ko) 2008-06-17 2011-04-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
CN103641907A (zh) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
CN104447980A (zh) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CA2747155A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
WO2010070251A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
BRPI0823376A2 (pt) 2008-12-15 2015-06-16 Zealand Pharma As Análagos de glucagon
EP2376521B1 (fr) 2008-12-19 2016-04-13 Indiana University Research and Technology Corporation Promédicaments insuliniques à base d'amide
EP2376097A4 (fr) * 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Promédicaments peptidiques de la superfamille du glucagon à base d'amide
EP2376520B1 (fr) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Analogues d'insuline
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112012018585A2 (pt) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
CA2797133C (fr) 2010-04-27 2019-08-06 Zealand Pharma A/S Conjugues peptidiques d'antagonistes du recepteur de glp-1 et de gastrine, et leur utilisation
CA2797095A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
BR112012028707A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
WO2011159895A2 (fr) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2803164C (fr) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Promedicaments insuliniques a base d'amide
CA2802897A1 (fr) 2010-06-24 2011-12-29 Zealand Pharma A/S Analogues de glucagon
JP2013540102A (ja) 2010-06-24 2013-10-31 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
JP6086067B2 (ja) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Ｇｉｐレセプター活性を示すグルカゴンアナローグ
PT2723367T (pt) 2011-06-22 2017-08-11 Univ Indiana Res & Tech Corp Co-agonistas do recetor da glucagina/glp-1
AU2012273365A1 (en) 2011-06-22 2014-01-16 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP3643306A3 (fr) * 2011-08-12 2020-08-26 Ascendis Pharma A/S Promédicaments liés à un support dotés de liaisons ester carboxylique réversibles
TW201326194A (zh) 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
SG11201406943XA (en) 2012-04-27 2014-12-30 Cytomx Therapeutics Inc Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
TR201815338T4 (tr) 2012-05-03 2018-11-21 Zealand Pharma As Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
JP6219308B2 (ja) * 2012-11-30 2017-10-25 株式会社糖鎖工学研究所 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法
RU2678134C2 (ru) 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
CN105188729B (zh) * 2013-05-07 2021-11-09 默克专利股份有限公司 用于针对肾毒性活性物质进行保护的缀合物
SI2994153T1 (sl) * 2013-05-07 2018-12-31 Merck Patent Gmbh Peptidi in konjugati peptid-učinkovina za renalno ciljanje
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015066279A2 (fr) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Anticorps activables se liant au récepteur du facteur de croissance épidermique et méthodes d'utilisation de ceux-ci
JP2017503474A (ja) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015089283A1 (fr) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Anticorps qui se lient à des anticorps activables et leurs procédés d'utilisation
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
WO2016049174A1 (fr) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Promédicaments insuliniques à base d'amide lipidique
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
JP6563614B1 (ja) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
CA3082827A1 (fr) * 2017-11-17 2019-05-23 Cytogel Pharma, Llc Agonistes polymeres de recepteurs mu-opioides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589356A (en) * 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement

Also Published As

Publication number Publication date
CA2265454A1 (fr) 1998-03-19
WO1998011126A1 (fr) 1998-03-19
AU724326B2 (en) 2000-09-14
AU4199497A (en) 1998-04-02
KR20000036015A (ko) 2000-06-26
IL128828A0 (en) 2000-01-31
JP2001505872A (ja) 2001-05-08
EP0932614A1 (fr) 1999-08-04

Similar Documents

Publication Publication Date Title
NZ334595A (en) Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
US5338668A (en) Opioid peptides derived from wheat proteins
DE60026300D1 (de) Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
EP1950224A3 (fr) Conjugués peptides pharmacologiquement actifs dotés d'une tendance réduite à l'hydrolyse enzymatique
Hooper et al. Metabolism of aspartame by human and pig intestinal microvillar peptidases
WO1997047593A3 (fr) Peptides
WO2013029182A1 (fr) Inhibiteurs de furine stables à base de peptide
SANO et al. OF4949, NEW INHIBITORS OF AMINOPEPTIDASE B IV. EFFECTS OF OF4949 AND ITS DERIVATIVES ON ENZYME SYSTEMS
Ukai et al. A Novel Synthetic Inhibitor of Endopeptidase
ATE248806T1 (de) N-3, 3-dimethylbutyl-l-asparaginsäure und ihre ester, verfahren zur herstellung dieser und das verfahren um daraus n-(n-(3,3-dimethylbutyl)-l- alpha-aspartyl)-l-phenylalanin-1-methylester herzustellen
Morihara et al. Effect of secondary interaction on the enzymatic activity of trypsin-like enzymes from Streptomyces
Berg et al. Formation of desTyr dynorphins 5–17 by a purified cytosolic aminopeptidase of rat brain
MURAMATSU et al. Synthetic inhibitors of trypsin, plasmin and chymotrypsin
DE69623635D1 (de) Mu-opioidligande: agonisten und antagonisten
US5776903A (en) Peptide derivatives usable as zinc endopeptidase 24-15 inhibitors
Benuck et al. Rat brain and kidney metalloendopeptidase: enkephalin heptapeptide conversion to form a cardioactive neuropeptide, Phe-Met-Arg-Phe-amide
Hersh Nomenclature for enkephalin degrading peptidases
NO993394D0 (no) Fremgangsmåte for fremstilling av rhizoferrin
Van Amsterdam et al. Synthesis of enkephalinase B inhibitors, and their activity on isolated enkephalin-degrading enzymes
EP0438600A4 (en) Enzymes which participate in c-terminal amidation, and production and use thereof
ARAÚJO-VIEL et al. Horse urinary kallikrein, II. Effect of subsite interactions on its catalytic activity
Oizumi et al. Lipoamidase is a multiple hydrolase
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1
Yasutake et al. Hydrolysis of cyclic depsidipeptides by trypsin or chymotrypsin